Targeting Cystic Fibrosis Using a Novel Inhalation Therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1121694

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Currently treatments for cystic fibrosis infection are via oral, intravenous or lengthy inhalation processes. This can lead to significant side effects, consequent poor patient compliance, and limited therapeutic efficacy. We will develop and test a novel high-dose inhalation dry power device containing an antibiotics for the rapid treatment of infection in cystic fibrosis therapy.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2018

Funding Scheme: Development Grants

Funding Amount: $421,545.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmaceutical Sciences

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cystic fibrosis | drug delivery | respiratory | respiratory infection | respiratory medicine

Related Links